Dalbavancin is an effective
antibiotic that is widely used to treat skin
infection. Our aim was to determine the effect of
dalbavancin administration on wound healing compared to that of
vancomycin and to elucidate if
epidermal growth factor receptor (EGFR),
matrix metalloproteinase 1 (MMP-1), MMP-9, and
vascular endothelial growth factor (
VEGF) could be involved in its therapeutic mechanism. A mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin
infection was established. Mice were treated daily with
vancomycin (10 mg/kg) and weekly with
dalbavancin at day 1 (20 mg/kg) and day 8 (10 mg/kg). After 14 days,
wounds were excised, and bacterial counts were performed. Wound healing was assessed by histological and immunohistochemical staining, followed by
protein extraction and immunoblotting. Our microbiological results confirmed that both
dalbavancin and
vancomycin are effective in reducing the bacterial load in
wounds. The
dalbavancin group showed a strong effect compared with infected untreated animals and the
vancomycin-treated group. The
wounds treated with
dalbavancin showed robust epidermal coverage with reconstitution of the regular and keratinized epidermal lining and well-organized granulation tissue with numerous blood vessels, although slightly less than that in the uninfected group. While in the
vancomycin-treated group the epithelium appeared, in general, still hypertrophic, the granulation tissue appeared even less organized. We observed elevated EGFR and
VEGF expression in both treated groups, although it was higher in
dalbavancin-treated mice. MMP-1 and MMP-9 were decreased in uninfected tissue and in both treated tissues compared with untreated infected
wounds. This study showed faster healing with
dalbavancin treatment that might be associated with higher EGFR and
VEGF levels.